Flemming Ørnskov
| Flemming Ørnskov | |
|---|---|
| Born | 1957/1958 (age 60–61)[1] |
| Nationality | Danish |
| Alma mater |
University of Copenhagen INSEAD Harvard University |
| Occupation | CEO, Shire plc |
| Salary | US$10,326,000 (total compensation, 2016)[1] |
Flemming Ørnskov (born 1957/58) is a Danish businessman who has been the chief executive officer (CEO) of Shire plc, a FTSE 100 speciality biopharmaceutical company since 30 April 2013, succeeding Angus Russell.[2] He previously worked for Bayer.
Ørnskov received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University.[1]
References
- 1 2 3 "Executive Profile: Flemming Ornskov". Bloomberg. Retrieved 4 September 2017.
- ↑ "Shire chief finds right prescription for growth". The Telegraph. Retrieved 20 March 2014.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.